Weight Management

Weight Loss Medications: Mounjaro, Ozempic, (GLP-1 & GIP agonists)

Expert care with proven medications like Mounjaro and Ozempic, decades of science, years of experience, and close medical monitoring to help you lose weight, improve health, and keep results for the long term.

What are GLP-1 and GIP agonists?

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists such as Mounjaro and Ozempic belong to a trusted, long-standing class of medications originally developed for type 2 diabetes. With decades of clinical research behind them, today they’re widely recognized for their benefits in weight management, blood sugar control, and overall metabolic health.

Our experience makes the difference

These medications may be trending, but the science behind them has been established for years. Our team of GPs brings a wealth of clinical experience in prescribing and managing these medications. We understand the nuances of dosing, side-effect support, and long-term monitoring thus, ensuring safe, personalised care tailored to your needs.

Safe progress through close healthcare monitoring

With regular consultations, blood tests, and lifestyle coaching, we help you achieve steady, sustainable progress toward your health goals—whether that's diabetes, healthy weight loss or weight management. Our attentive care combines proven therapies with continuous support to help you succeed.

Common Questions Our Patients Ask

1. How long do patients typically take these medications?

Mounjaro, Ozempic and Wegovy are most effective when taken long-term, often extending beyond one year. Clinical trials frequently run for 72–84 weeks (about 18–21 months), and some individuals continue treatment beyond this under medical supervision. Ultimately, the length of treatment is tailored to each patient's goals and health.

2. How much weight can I expect to lose?

Recent research underscores just how effective these medications can be:

• A head-to-head trial in The New England Journal of Medicine (May 2025) compared tirzepatide (Mounjaro) to semaglutide (Ozempic/Wegovy) in 751 non-diabetic adults. After 72 weeks:

  • Mounjaro users lost 20.2% of their body weight vs. 13.7% with Ozempic/Wegovy.

  • Waist circumference dropped by 18.4 cm with Mounjaro vs. 13 cm with Ozempic/Wegovy.

• Across the SURMOUNT clinical trials, Mounjaro consistently reduced both body weight and waist circumference regardless of how long someone had obesity—with weight losses of ~21% at the same dose over 72 weeks in participants with varying durations of obesity.

3. Are these drugs safe to use?

When prescribed and monitored by experienced clinicians, Mounjaro, Ozempic and Wegovy are considered safe and well tolerated. Common side effects, mainly during dose initiation and escalation, include mild gastrointestinal symptoms like nausea, constipation, or diarrhoea and can be managed with our guidance.

4. Will I keep the weight off after stopping?

Studies show that stopping treatment without lifestyle changes often leads to weight regain. However, maintaining healthier habits built during treatment can help preserve your progress. Because of this, many patients stay on therapy longer while transitioning to sustainable lifestyle routines to support long-term success.

Take the Next Step

Curious if Mounajro, Ozempic or Wegovy is right for you? Our experienced GPs are here to guide you. From tailored treatment planning to close monitoring and lifestyle support. Let Knightsbridge Doctors help you achieve meaningful, lasting results.